2026 Q2 - tulosraportti
76 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,51%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 108 | - | - | ||
| 66 | - | - | ||
| 187 | - | - | ||
| 51 | - | - | ||
| 37 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·30 min sittenNovo/ CagriSema: A very strong and clinically relevant result with 25 pct. weight loss for women https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
·49 min sittenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-stærkt-og-klinisk-relevant-resultat-med-25-pct-vægttab-for-kvinder
·1 t sitten · MuokattuHalllooo market - Latest Reuters news is very, very interesting: "Two thirds of REDEFINE 1 were women, and in this very large group CagriSema hit exactly the 25 % that the market had originally hoped for." Boom - For at least half of the buyers in the market, CagriSema is just as good as (and for some even better than) Zepbound.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |
2026 Q2 - tulosraportti
76 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
4,51%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·30 min sittenNovo/ CagriSema: A very strong and clinically relevant result with 25 pct. weight loss for women https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
- ·49 min sittenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-stærkt-og-klinisk-relevant-resultat-med-25-pct-vægttab-for-kvinder
- ·1 t sitten · MuokattuHalllooo market - Latest Reuters news is very, very interesting: "Two thirds of REDEFINE 1 were women, and in this very large group CagriSema hit exactly the 25 % that the market had originally hoped for." Boom - For at least half of the buyers in the market, CagriSema is just as good as (and for some even better than) Zepbound.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 108 | - | - | ||
| 66 | - | - | ||
| 187 | - | - | ||
| 51 | - | - | ||
| 37 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |
2026 Q2 - tulosraportti
76 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. | ||
2025 Q3 - tulosraportti 5.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,51%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·30 min sittenNovo/ CagriSema: A very strong and clinically relevant result with 25 pct. weight loss for women https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-st%C3%A6rkt-og-klinisk-relevant-resultat-med-25-pct-v%C3%A6gttab-for-kvinder
- ·49 min sittenLige modtaget fra Novo (15:00) Investigational CagriSema 2.4 mg / 2.4 mg showed significant weight loss among women overall and across pre-, peri- and postmenopausal stages in two post hoc analyses from REDEFINE 1, a phase 3 trial in adults with obesity or overweight¹,² Across the two analyses, CagriSema use was associated with reductions in abdominal fat, as measured by waist circumference, among women overall and across menopause stages¹,² CagriSema is an investigational once-weekly combination of semaglutide, a GLP-1 receptor agonist (RA), and cagrilintide, a long-acting amylin analog Plainsboro, New Jersey, US and Bagsværd, Denmark, 20 October 2026 – Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of 2,309 women with obesity or overweight, CagriSema 2.4 mg / 2.4 mg (cagrilintide 2.4 mg and semaglutide 2.4 mg) was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, if all patients adhered to treatment (efficacy estimand*).1 In a second analysis of 1,902 women with overweight or obesity assigned post hoc by menopausal status, average weight loss at week 68 was 26.7%, 24.8% and 23.1% in premenopausal, perimenopausal and postmenopausal women, compared with 2.1%, 1.7% and 2.6% with placebo, respectively (efficacy estimand*).2 “Many women with obesity or overweight experience weight gain as they move through menopause, and it is important to explore investigational products such as CagriSema across the reproductive lifespan,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “CagriSema has the potential to be the first amylin analog and GLP-1 RA combination therapy for weight management, and these REDEFINE 1 data show it was associated with significant weight loss for women with obesity or overweight. These findings add to the body of evidence from the REDEFINE clinical program.” Women experience major hormonal shifts throughout the different stages of menopause, which can increase abdominal fat accumulation and impact body composition, weight and cardiometabolic risk.2,3 More than 86 million women in the U.S. are aged 40 and older, the years in which perimenopause, menopause and postmenopause occur,4 yet reproductive stage is rarely evaluated as a factor in obesity research.5 In the post hoc analysis of all 2,309 women enrolled in the REDEFINE 1 trial, treatment with CagriSema 2.4 mg / 2.4 mg was associated with an average weight loss of 25.0% at week 68, compared with 3.0% with placebo, as well as meaningful improvements in waist circumference – a secondary endpoint of the REDEFINE 1 trial and a measure associated with abdominal fat.1 Change in bodyweight and waist circumference, and achievement of weight-loss targets, among women in REDEFINE 1 at week 68, efficacy estimand results*1 Outcome at week 68 CagriSema 2.4 mg / 2.4 mg (n=1,441) Semaglutide 2.4 mg (n=199) Cagrilintide 2.4 mg (n=208) Placebo (n=461) Baseline bodyweight, mean 101.5 kg 100.2 kg 101.4 kg 102.2 kg Change in bodyweight –25.0% a –19.0% –13.4% –3.0% Change in waist circumference –20.5 cm a –17.4 cm –11.7 cm –4.7 cm Achieved ≥10% bodyweight loss 93.3% a 82.2% 62.0% 12.7% Achieved ≥20% bodyweight loss 68.7% a 38.0% 17.9% 1.8% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-sex interaction testing was not performed In a separate post hoc analysis, 1,902 women with overweight or obesity in REDEFINE 1 who received CagriSema 2.4 mg / 2.4 mg or placebo were evaluated by menopausal stage. Menopause status was derived post hoc using age, medical history, and recorded symptoms and was not based on prospectively collected reproductive staging or biochemical confirmation. CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.2 Change in bodyweight from baseline to week 68, efficacy estimand results*2 Post hoc analysis group by menopause status (CagriSema n / placebo n) CagriSema 2.4 mg / 2.4 mg (change from baseline) Placebo (change from baseline) Premenopausal (408 / 122; baseline 104.3 / 107.1 kg) –26.7% a –2.1% Perimenopausal (256 / 81; baseline 102.7 / 99.6 kg) –24.8% a –1.7% Postmenopausal (530 / 168; baseline 99.1 / 99.3 kg) –23.1% a –2.6% a Statistically significant compared with placebo, estimated mean, p<0.0001; p values were not adjusted for multiplicity and formal treatment-by-subgroup interaction testing was not performed “This post hoc analysis from REDEFINE 1 offers new insight into weight loss with investigational CagriSema in women grouped by reproductive life stage,” said Maria D. Hurtado Andrade,https://proinvestor.com/forum/topic/560119/novo-cagrisema-et-meget-stærkt-og-klinisk-relevant-resultat-med-25-pct-vægttab-for-kvinder
- ·1 t sitten · MuokattuHalllooo market - Latest Reuters news is very, very interesting: "Two thirds of REDEFINE 1 were women, and in this very large group CagriSema hit exactly the 25 % that the market had originally hoped for." Boom - For at least half of the buyers in the market, CagriSema is just as good as (and for some even better than) Zepbound.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 108 | - | - | ||
| 66 | - | - | ||
| 187 | - | - | ||
| 51 | - | - | ||
| 37 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 47 645 | 47 645 | 0 | 47 645 |
| Anonyymi | 1 774 928 | 1 774 928 | 0 | 0 |